Early Phase 1 Depression and Anxiety Trial, Recruiting NCT06898788 Sponsor: University of California, San Francisco Condition: Depression and Anxiety
Back to Depression And Anxiety

Early Phase 1 Depression and Anxiety Trial, Recruiting

NCT06898788
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 15 to 24 years (both female and male)
  • People who are fluent in English
  • People who have access to a smartphone, tablet, or computer that can run the program "Zoom" for remote appointments
  • People who have been diagnosed with a primary depressive disorder according to DSM-5 criteria — this includes Major Depressive Disorder, Persistent Depressive Disorder, or Other Specified Depressive Disorder — confirmed through a structured diagnostic interview
  • People who are currently under the care of a primary care doctor and/or a mental health professional
  • People who have been taking an SSRI antidepressant medication for at least 8 weeks
  • People whose depression symptom score on the BDI-II questionnaire is greater than 13 (indicating at least mild depression)

Who may not be able to join:

  • People who have a current diagnosis of another mental health condition under DSM-5, unless it is an anxiety disorder or ADHD and the depressive disorder is the main diagnosis
  • People currently being treated with stimulant medication for ADHD, unless the dosage has been stable and there are no plans to change it for at least 8 weeks
  • People who have a current diagnosis of a personality disorder, as assessed by a structured clinical interview
  • People who have taken oral probiotic supplements in the month before the phone screening
  • People who have taken oral or intravenous (IV) antibiotic medication in the month before the phone screening
  • People who have eaten fermented foods (such as yogurt or kombucha) in the month before the phone screening
  • People who have taken oral antioxidant or omega-3 supplements within 6 weeks before the phone screening
  • People who currently drink more than 2 alcoholic drinks per week
  • People who have smoked more than 5 cigarettes in the last 6 months, or have used a pipe or hookah even once in the last month
  • People who have plans to make significant changes to their diet or lifestyle
  • People who have a weakened immune system
  • People who have allergies to milk, soy, or yeast
  • People who have not yet reached a certain stage of physical development known as Tanner Stage 3 (confirm with trial site)
  • People who are currently experiencing active thoughts of suicide that would require hospital admission, or who have a specific plan or intention to attempt suicide, as assessed by a standardised scale
  • People who have made a suicide attempt within the past 6 months that required hospitalisation or an emergency department visit
  • People whose depression has not responded to two or more adequate treatment attempts with two different first-line SSRI antidepressant medications
  • People who are unable to have an MRI scan for any reason (for example, having metal braces)
  • People who are currently pregnant or who plan to become pregnant during the study period; people of reproductive capability who are eligible to participate will be asked to use at least one approved method of contraception until their second MRI scan is completed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Cherry Leung, PhD, RN, University of California, San Francisco

Phone: (415) 502-0955

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
15 May 2025
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Left hippocampus-precuneus resting state functional connectivity; Beta diversity; Generic Assessment of Side Effects - Probiotics (GASE-P)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov